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Predictive modela b s t r a c t
Introduction: About 30% of patients request breast reconstruction following surgery for breast cancer, but
radiation therapy negatively influences the outcome. Post-reconstruction radiotherapy is associated with
more complications, including more severe capsular contracture and inferior cosmetic results. In general,
less fibrosis is seen if autologous reconstruction is performed after radiotherapy, so surgeons will often
delay reconstruction until after radiotherapy is complete. Drawbacks to this approach include additional
surgery, recuperation, cost, and an extended reconstructive process. Randomised clinical trials are
required to determine the best approach.
Methods and analysis: The aim of this cross-sectional pilot study is to see if it is feasible to recruit women,
and gather the required data. This information will be used to design a subsequent, larger study whose
aim is to identify factors that increase the risk of radiation-induced fibrosis, and use these to develop a
personalised risk-prediction tool, to enable the clinician and patient to have a more informed discussion
when treatment for breast cancer is being discussed. Identification of the risk factors will also enable the
development of methods to minimise the risk, which would have applications in other medical condi-
tions where fibrosis is a problem. In addition, the project will develop objective methods of assessing
fibrosis, and will determine the psychological and economic impacts that fibrosis has affected individuals.
A better understanding of the long-term effects of radiotherapy on normal tissues such as the heart and
lungs may also have applications in other medical conditions where fibrosis is a problem.
Ethics and dissemination: The study has been submitted for ethical approval (REC reference). Findings will
be made available to patients and clinicians through presentations at national and international meet-
ings, peer-reviewed publications, social media and patient support groups.
Trial registration: Registered on ClinicalTrials.gov (after REC approval).
 2019 Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open access article under
the CC BY license (http://creativecommons.org/licenses/by/4.0/).Strengths and limitations
– This study will establish feasibility, assess patient acceptability,
and inform the design of a randomised clinical trial to answer
the question of the best approach to take when planning recon-
structive surgery.– The clinical team will work with engineers to develop an objec-
tive measure of radiation-induced fibrosis.
– Objective methods alone may not capture the full extent of
radiation-induced fibrosis.
– Patient reported outcome measures will be included to provide
a more comprehensive assessment of the effects of radiation-
induced fibrosis.
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1.1. Context
Breast cancer is the most common cancer to affect women in
Europe, having a lifetime risk of 1 in 9. It is an increasingly treat-
able disease, and 10-year survival now exceeds 80%. The primary
treatment for breast cancer is surgery, which is often used in con-
junction with adjuvant therapies such as radiotherapy. Given the
high breast cancer survival rate, an increasing number of women
will live for many years with the consequences of their surgical
and therapeutic treatment [1].
Women who receive radiation therapy as part of their treatment
for breast cancer are at risk of late side-effects including radiation-
induced fibrosis. This is an irreversible condition where there is an
excessive formation of fibrous connective tissue which causes struc-
tural and functional changes. Fibrosis of the breast can cause harden-
ing; if severe, the breast can become noticeably smaller and firmer.
Fibrosis of the lung can cause a dry cough or shortness of breath.
Fibrosis of heart tissue can cause serious problems, including heart
failure. These problems can adversely impact the physical, psycho-
logical, social and economic well-being of an individual.
Approximately 30% of patients request breast reconstruction
following breast cancer surgery [2]. It is generally accepted that
radiation negatively influences the outcome of reconstruction in
relation to late complications and aesthetic outcome [3]. Advances
in multimodality treatments and subsequent significant improve-
ments in survival impose greater expectations from patients on
the quality of their aesthetic surgical outcome. Several studies
advocate avoidance of post-reconstruction radiotherapy due to
higher prevalence of complications, unpredictable volume loss,
and unsatisfactory aesthetic outcomes [4,5]. Post-reconstruction
radiotherapy is associated with more complications, including
more severe capsular contracture and inferior cosmetic results, in
implant-based compared to autologous reconstruction [6,7], which
can be successful, although patients with specific risk factors, such
as diabetes mellitus and smoking, should be aware of increased
complication rates [8]. In general, less fibrosis is seen if autologous
reconstruction is performed after radiation therapy [9], so sur-
geons will often delay reconstruction until after radiation therapy
is complete. Drawbacks to this approach include additional surgery
and an extended reconstructive process.1.2. Preliminary work
The commonly reported incidence of radiation-induced fibrosis
(RIF) is 10–15% [10], although 23% has been reported [11]. Mani-
festations of RIF in the breast may result in pain and cosmetic
deformities. 41–45% of patients with fibrosis experience breast
pain. Furthermore, the severity of fibrosis is directly related to
the degree of morbidity, ranging from mild skin changes such as
firmness on palpation to severe handicapping sclerosis many years
after radiation exposure [12]. The development of radiation-
induced fibrosis is influenced by multiple factors, including the
radiation dose and area, fractionation schedule, previous or con-
current treatments, genetic susceptibility, and comorbidities
[13,14]. RIF can significantly impact patients’ quality of life. Under-
standing the mechanisms of RIF-induced changes is essential to
developing effective strategies to prevent long-term disability
and discomfort following radiotherapy.1.3. Study aims and outcomes
The aim of the RIF cross-sectional pilot study is to see if it is
feasible to recruit women, and gather the required data. Thisinformation will be used to design a subsequent, larger study
whose aim is to identify factors that increase the risk of
radiation-induced fibrosis, and use these to develop a person-
alised risk-prediction tool, to enable the clinician and patient to
have a more informed discussion when treatment for breast can-
cer is being discussed. Identification of the risk factors will also
enable the development of methods to minimise the risk, which
would have applications in other medical conditions where fibro-
sis is a problem. In addition, the RIF project will develop objec-
tive methods of assessing fibrosis, and will determine the
psychological and economic impacts that fibrosis has affected
individuals.
Most of the data used in the project will be readily available
from the patients’ medical notes and assessments made during
routine standard of care (e.g. MRI and other images; information
about the tumour size, location, type; etc.). Study-specific assess-
ments will include 2D and 3D imaging of the unclothed torso,
and self-completed questionnaires.
The objective assessments of outcome will eventually enable
standardisation over time and across geographic locations. The
psychological and economic assessments will empower patients
to appreciate the impact that this side effect may have on their life
outside of hospital.
2. Methods and design
2.1. Study design
This is a cross-sectional observational study on a cohort of
women who have completed treatment for early breast cancer
more than one year ago (no upper time limit).
2.2. Setting
This study will take place at a single site (Royal Free Hospital,
London, UK) in 2019 and 2020. All patient-specific research activ-
ities and data collection will be completed in less than one day;
there will be no follow-up investigations.
2.3. Participants
See Fig. 1. Suitable patients will be identified from the hospital
notes (paper and electronic). The patient will then be approached
by a member of the team and the RIF study discussed with her. If
she is still interested, the patient will be given an information leaf-
let and consent form to read and discuss with family and friends.
Once the patient provides written informed consent she will be
deemed a participant in the study, although participation can be




 Women who have undergone breast surgery for early breast
cancer (with or without reconstruction) and received radiother-
apy more than one year ago (no upper limit).
 Written informed consent obtained.
2.4.2. Exclusion criteria
 Unable to provide written informed consent.
 Younger than 18 years.




EQ-5D-5L A standardised instrument developed by the
EuroQol Group (https://euroqol.org/eq-5d-
instruments/) as a measure of health-related
quality of life used in a wide range of health
conditions and treatments.
EORTC-QLQ-C30 & BR23 Developed in 1988, consists of a core generic




ASI-R (composed of SES
and MS subscales)
Appearance Schemas Inventory-Revised (ASI-R)
is a 20-item measure with two subscales to
measure cognitive-behavioural investment in
one’s own appearance—Self-Evaluative Salience
(12 items) and Motivational Salience (8 items)
(http://www.body-images.com/assessments/)
The Body Image Scale
(Hopwood)
A short (10-item) body image scale (BIS) for use
in clinical trials. (Hopwood et al. (2001) Eur J
Cancer. 37(2):189–97)
Travel Questionnaire A non-validated questionnaire asking about




A non-validated questionnaire asking about
patient experience in the way study information
was presented.
Fig. 1. Study Flow Chart.
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No formal sample size calculations have been performed for this
pilot study. A sample size of 50 patients is considered sufficient to
determine if patients can be recruited to a larger study in a reason-
able period of time, and to determine if a complete set of data can
be obtained on each patient, including the completion of all question-
naires. In addition, analysis of the data will enable estimation of the
statistical power of a larger study designed with 90% power and two-
sided 5% significance with a small standardised effect size [21].
2.6. Consent
The Patient Information Leaflet will be given to the patient dur-
ing the recruitment process. Written informed consent will then be
obtained using the consent form which will also be signed by the
physician who explained the study to the patient. A copy of the
consent form will be retained in site file, and a record of the con-
sent process made in the patient’s hospital notes.
2.7. Interventions & outcomes
After consent, each study patient will have the following assess-
mentsand interventions, includingheight,weight, andbraandcupsize
recorded by a member of the clinical team. The estimated time taken
for photography and questionnaire completion is about 50 min. This
will take place once per patient; there will be no follow-up.
2.7.1. Questionnaires
See Table 1.2.7.2. Images
Each subject will have anonymised 2D (digital SLR) and 3D
images taken of her unclothed torso (neck to navel) at various
angles according to a pre-specified protocol.
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The primary objective is to determine the rate at which eligible
women can be identified and recruited into the study.
The secondary objective is to determine if it is feasible and
acceptable to patients to gather the required clinical data, includ-
ing 2D and 3D imaging and health-related quality of life
questionnaires.
2.8. Participant withdrawal
If a participant, who has given informed consent, loses capacity
to consent during the study, she will be withdrawn from the study.
Identifiable data already collected with consent would be retained
and used in the study. Participants who stop the study early will be
replaced to maintain the sample size.
2.9. Patient and public involvement
The aim of this study is to see if it is feasible to collect the data,
and if patients are happy with the assessments. If successful, there
will be extensive public and participant involvement to assist in
the design of a larger subsequent study.
2.10. Data collection
All data will be handled in accordance with the Data Protection
Act 1998. The Case Report Forms (CRFs) will not bear the partici-
pant’s name or other directly identifiable data. The participant’s
study identification number will be used for identification. The
Staff Delegation of Responsibilities Log will identify all trial per-
sonnel responsible for data collection, entry, handling and manag-
ing the database. The data custodian for this study is the Chief
Investigator (CI, Afshin Mosahebi).
2.11. Statistical analyses
No formal analysis of the primary outcome measure will be
undertaken. Most of the analyses will be descriptive; continuous
variables will be summarised using the mean, standard deviation,
median, and interquartile range; categorical variables will be sum-
marised as frequencies and proportions; all estimates will include
confidence intervals. Data will be transformed if required.
Recruitment rate will be calculated as number of participants
providing written informed consent divided by the time period.
Numbers of patients recruited per month will be tabulated.
The completeness of data obtained from each patient will be
estimated from the data actually obtained divided by the data
expected to be obtained; this will be broken down into data source
types (e.g. photographs, questionnaires, etc.).
Details of the number of eligible patients will be collected suf-
ficient for the completion of a CONSORT diagram (http://www.con-
sort-statement.org/).
A Statistical Analysis Plan (SAP) will be drafted and agreed
before the first analysis. Any deviation(s) from the agreed plan will
be described and justified.
2.12. Sources of bias
Sufficient information on all eligible patients will be collected to
populate the CONSORT diagram; this will enable a description of
the characteristics of the cohort in this population-based study,
in order to determine if there had been selection bias, and to gauge
the extent of non-response bias and volunteer bias. Use of objec-
tive measures will minimise ascertainment bias, but the patient-
reported questionnaires will undoubtedly be prone to responsebias. Estimates of these biases will be invaluable for the design of
a randomised clinical trial.2.13. Study organisation and administration
The Study Management Group (SMG) will be responsible for the
day-to-day management of the study, and will include the CI, Clin-
ical Co-investigator, and statistician. The role of the group is to
monitor all aspects of the conduct and progress of the study,
ensure that the protocol is adhered to and take appropriate action
to safeguard participants.
Members of the SMG will sign a Terms of Reference document
that will specify elements such as composition of the group/quo-
rum requirements, how meetings are convened and conducted,
who is responsible for providing the group with information, etc.2.14. Ethics and dissemination
The study has been submitted for ethical approval from the
Research Ethics Committee (REC reference). The results of the
study will be published in peer-reviewed publications and will
be presented at relevant national and international conferences.2.15. Availability of data
The SMG will control the final study dataset and any requests
for access must adhere to the current SMG data sharing policy.
The protocol, sample case report forms and participant information
are available on upon request to the corresponding author.2.16. Study status
The study is expected to be opened to recruitment in April 2019.3. Discussion
Changes to appearance and body image as a consequence of
breast cancer treatment can be extensive and enduring [15,16].
Women have reported that these changes are amongst the most
difficult aspects of the disease [15,17]. Whilst a growing body of
research has examined various aspects of breast cancer treatment
on body image, to date, limited consideration has been given to the
impact of radiation-induced fibrosis on body image amongst
women with breast cancer. Assessment of the impact of any treat-
ment on body image is needed [18].
This study is part of a programme designed to explore the
impact of radiation-induced fibrosis on both quality of life and
body image, and examine the sociodemographic, clinical and psy-
chosocial factors that predict adjustment over time. A theory of
adjustment to body images changes amongst patients with cancer
[19] highlights the importance an individual places on appearance
(appearance investment). The need to include assessment of the
importance placed on appearance in research and clinical work
with radiotherapy patients has been highlighted [20]. Patients
who place greater importance on their appearance are more vul-
nerable to a poor adjustment when facing changes to appearance.
Previous research [18] has shown that the level of investment in
appearance predicts subsequent body image, so higher initial
levels of investment in appearance would be associated with poor
quality of life and body image.
The information from this study will be used to design a ran-
domised clinical trial whose aim is to identify personalised strate-
gies to reduce the risk of radiation-induced fibrosis. This work will
have implications in other medical conditions where fibrosis is a
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Registration will be made soon after ethics approval.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.isjp.2019.02.002.
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